NASDAQ · ILMN

Illumina, Inc.

Healthcare · Medical - Diagnostics & Research

$201.27▼ 1.82% ($3.73)at close

After hours$200.01▼ 0.63%7:30 PM ET

52-week

$88.00$231.81

Market cap

What the market price implies · Reverse DCF

To support a price of $201.27, this model requires revenue to grow by 20.92%/yr over the next 10 years, compounded annually.

Historical revenue grew by -1.06%/yr over the past 4 years. The required annual growth rate is 21.97 percentage points higher.

Selected forecast · Base scenario

1.46%/yr · actual 10-year annualized revenue growth

Year 1 growth: 2.28%

Market-implied · Base operating assumptions + edited margins

20.92%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$201.27

Estimated value / share

$51.42

Base scenario

This estimate is 74.45% below the price used.

USD · TTM ending 2026-06-28

Year 1 growth 2.28% · Ending margin 22.01% · Discount rate 12.46%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-28
Data refreshed: Sep 11, 2026, 12:27 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 110.78%Revenue (TTM): 4.93%FCF (TTM): -8.92%P/FCF: 20th pct

What changed

The stock rose 110.78% over the last year. Revenue grew 4.93% over the trailing twelve months. Operating margin moved from 31.5% to 20.97%. Free cash flow declined 8.92% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at 20.97%. A decisive move in revenue — currently up 4.93% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies.

CEOJacob Thaysen

SectorHealthcare

IndustryMedical - Diagnostics & Research

Employees8,600

IPO dateJul 28, 2000

https://www.illumina.com

Market multiples

Forward P/E—

EV/EBITDA15.09

Enterprise value$21.98B

Stock splits

Sep 23, 2008↑ Forward

Every 1 shares became 2

+100%

Profitability & growth

Revenue growth9.65%

Gross margin66.79%▲1.3ppvs FY2024

Operating margin20.97%▲39.0ppvs FY2024

ROE32.38%▼1.0ppvs FY2025

Analyst consensus

RatingBuy

Target price$210.67▲4.67%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Oct 29, 2026

Q4 FY26 · EPS est $1.38 · Revenue est $1.15B

View